

Drug Utilization Review Board

Meeting Minutes

Thursday, March 14, 2019
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Kumar Shah, MSc, PEng, Board Chair
Neal Catalano, PharmD
Judith Turner, DVM, PharmD

Sharon Weinstein, MD
Katherine Smith, PharmD
Susan Siegfried, MD

Board Members Excused:

Aesha Drozdowski, PharmD
Jennifer Brinton, MD

Kyle Kitchen, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Strohecker, PharmD, Pharmacy
Director
Bryan Larson, PharmD
Joe Busby, RPh, MBA

Merelynn Berrett, RN
Heather Santacruz, RN

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez

Other Individuals Present:

Chad Wheeler, Greenwich Biosciences
Contessa Fincher, Eisai
Karen Einbinder, Greenwich Biosciences
Elise Conlee, Greenwich Biosciences

Michelle Bice, Gilead
Valerie Gonzales, U of U
Rob Booth, Allergan

Meeting conducted by: Board Chair

1. **Welcome & Housekeeping:** Kumar Shah opened the meeting and announced a quorum.
 - a. Jennifer Strohecker discussed tentative topics that will be covered at upcoming meetings, including a DRRC report to the DUR board in April, and possible topics for other meetings.
2. **Review and Approval of February Minutes:** Katherine Smith noted an error in the pending minutes; Aesha Drozdowski was listed as being in attendance, but was not present at the February meeting. Neal Catalano made a motion to approve the minutes from February with the noted corrections. Katherine Smith seconded the motion. Four in favor with Sharon Weinstein and Susan Siegfried abstaining. Motion passed.
3. **Cannabidiol and Stiripentol for the treatment of seizures associated with Lennox-Gastaut and Dravet Syndromes:**

a. Information

1. Elena Martinez presented peer reviewed research and guidelines regarding the use of cannabidiol and stiripentol for the treatment of Lennox-Gastaut and Dravet Syndromes.

b. Public Comment

1. Elise Conlee from Greenwich Biosciences presented information pertaining to cannabidiol.
2. Contessa Fincher from Eisai Pharmaceuticals presented information pertaining to Fycompa.

c. Board Discussion

1. Board discussion focused on the existing prior authorization criteria for Epidiolex (cannabidiol) and recommended updates to those criteria.

d. Board Action

1. Motion to update prior authorization criteria for cannabidiol:

1. Change “Trial and failure of at least one agent FDA approved for the treatment of Lennox-Gastaut syndrome (LGS) or Dravet syndrome” to “Trial and inadequate response to at least one agent used for the treatment of Lennox-Gastaut syndrome (LGS) or Dravet syndrome”
2. Remove criteria referring to drug interactions and contraindications
3. Change initial authorization from 3 months to 6 months
4. Motion made by Sharon Weinstein. Second: Judith Turner. All in favor, motion passed.

4. **Public Meeting Adjourned:** Neal Catalano motioned to close the meeting. Sharon Weinstein seconded the motion. Unanimous Approval.

5. **The next meeting scheduled for** Thursday, April 11, 2019 DRRC report to DUR Board.

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>